Payers await Medicare preliminary decision on Aduhelm coverage January 3, 2022 Auto Bot Payer Issues 0 Biogen slashed the price of its controversial Alzheimer’s drug Aduhelm after a problematic rollout, but the move has still done little to encourage Medicare to cover the controversial drug.